Evaluating Prognosis in AL Amyloidosis: Can LV Strain Play a Role?

Rodney H Falk¹, Vasvi Singh², Sharmila Dorbala^{1

2}

Affiliations

¹ Amyloidosis Program, Brigham and Women's Hospital, Boston, Massachusetts, USA.
² Division of Nuclear Medicine and Department of Radiology, Brigham and Women's Hospital, Boston, Massachusetts, USA.

Editorial

Rodney H Falk et al. JACC CardioOncol. 2020.

. 2020 Jun 16;2(2):232-235.

doi: 10.1016/j.jaccao.2020.05.014. eCollection 2020 Jun.

Rodney H Falk¹, Vasvi Singh², Sharmila Dorbala^{1

2}

¹ Amyloidosis Program, Brigham and Women's Hospital, Boston, Massachusetts, USA.
² Division of Nuclear Medicine and Department of Radiology, Brigham and Women's Hospital, Boston, Massachusetts, USA.

No abstract available

Keywords: global longitudinal strain; light chain amyloidosis; prognosis.

Figures

Incremental Value of Global Longitudinal Strain for Predicting Survival in Patients With Advanced AL Amyloidosis.
Lee Chuy K, Drill E, Yang JC, Landau H, Hassoun H, Nahhas O, Chen CL, Yu AF, Steingart RM, Liu JE. Lee Chuy K, et al. JACC CardioOncol. 2020 Jun;2(2):223-231. doi: 10.1016/j.jaccao.2020.05.012. Epub 2020 Jun 16. JACC CardioOncol. 2020. PMID: 33117993 Free PMC article.

1. Skinner M., Anderson J., Simms R. Treatment of 100 patients with primary amyloidosis: a randomized trial of melphalan, prednisone, and colchicine versus colchicine only. Am J Med. 1996;100:290–298. - PubMed
1. Jaccard A., Moreau P., Leblond V. High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis. N Engl J Med. 2007;357:1083–1093. - PubMed
1. Koyama J., Falk R.H. Prognostic significance of strain Doppler imaging in light-chain amyloidosis. J Am Coll Cardiol Img. 2010;3:333–342. - PubMed
1. Palladini G., Campana C., Klersy C. Serum N-terminal pro-brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis. Circulation. 2003;107:2440–2445. - PubMed
1. Dispenzieri A., Gertz M.A., Kyle R.A. Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis. J Clin Oncol. 2004;22:3751–3757. - PubMed